

# 3. Bölüm

## COVID-19 EPİDEMİYOLOJİSİ


*Hasan SÖZEL<sup>1</sup>  
Üstün YILMAZ<sup>2</sup>*

### GİRİŞ

Koronavirüsler önemli insan ve hayvan patojenleridir. Bu virüs grubu birçok farklı hayvandan izole edilmekle birlikte yarasalar doğal rezervuar olarak kabul edilir (1,2). Son zamanlarda tespit edilen koronavirüslerin (SARS-CoV (2002), MERS-CoV (2012)) hayvanların yanında insanlarda ciddi akut solunum yolu enfeksiyonlarına ve nozokomiyal enfeksiyonlara neden olduğu saptanmıştır. İnsandan insana bulaşabilen çeşitli alt tipler (HCoV-229E, HCoV-OC43, HCoV-NL63 ve HKU1-CoV) saptanmıştır. İnsanlar arasında dolaşan bu alt türler çoğunlukla soğuk algınlığına sebep olan virüslerdir. 2019'un sonunda, Çin'in Hubei eyaletindeki bir şehir olan Wuhan'da bir dizi pnömoni vakasının nedeni olarak yeni bir koronavirüs tespit edildi (3,4). Hastalık Çin ve tüm dünyada hızla yayılmasının ardından küresel bir salgın olarak ilan edildi. Şubat 2020'de Dünya Sağlık Örgütü, 2019 koronavirüs hastalığı anlamına gelen COVID-19 hastalığını tanımladı (5). Hastalık yaygın olarak halsizlik, genel vücut ağrısı, ateş, boğazda yanma, öksürük ve nefes darlığı gibi semptomlarla kendini göstermekle birlikte asemptomatik olarak da görülebilmektedir (6). Ayrıca hastalığın üst solunum yolu enfeksiyonundan şiddetli pnömoniye, kardiyovasküler sistem, sindirim sistemi, sinir sistemi ve böbrekler dahil olmak üzere birçok organda işlev bozuk-

<sup>1</sup> Öğr. Gör. Dr., Hasan SÖZEL, Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları AD., dr07hasan@hotmail.com

<sup>2</sup> Uzm. Dr., Üstün YILMAZ, SBÜ Antalya Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, ustunfy@gmail.com



Şekil 7: Türkiye’de Günlük COVID-19 Ölüm Sayılarının Seyri

**Kaynak:** <https://www.worldometers.info/coronavirus/#countries>

Türkiye’de günlük vaka sayılarıyla korele seyreden günlük ölüm sayısını gösteren grafik şekil-7’de verilmiştir. 18 Ağustos 2021 tarihi itibarıyla Türkiye’de günlük ölüm sayısı 168, toplam ölüm sayısı da 53.675 olarak bildirilmiştir (49).

## SONUÇ

Mevcut gelişmeler, veriler ve hergeçen gün ortaya çıkan yeni varyant suşlar da göz önüne alındığında COVID-19’un epidemiyolojik verilerinin hızlı değişimi kaçınılmazdır.

## KAYNAKLAR

1. Cui, J., Li, F. & Shi, Z. Origin and evolution of pathogenic coronaviruses. *Nature Reviews Microbiology* 2019; 17 (3): 181- 192. doi: 10.1038/s41579-018-0118-9
2. Yu P, Hu B, Shi ZL, et al. Geographical structure of bat SARS related coronaviruses. *Infection Genetic and Evolution* 2019; 69: 224-229. doi: 10.1016/j.meegid.2019.02.001
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020 Feb 28. doi: 10.1056/NEJMoa2002032.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497- 506. doi: 10.1016/S0140-6736(20)30183-5
5. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. <http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020> (Accessed on February 12, 2020).
6. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome

- coronavirus-2 (SARSCoV-2; Coronavirus Disease-19). *Clin Exp Pediatr* 2020; 63: 119-24.
7. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020 Feb 24. pii: S2213-2600(20)30079-5. doi: 10.1016/S2213- 2600(20)30079-5.
  8. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579 (7798): 270-273. doi: 10.1038/s41586- 020-2012-7
  9. Lam TT-Y, Shum MH-H, Zhu H-C, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. *bioRxiv.* 2020:2020.02.13.945485
  10. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med* 2020.
  11. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020; 396:313.
  12. Shen Y, Li C, Dong H, et al. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. *JAMA Intern Med* 2020; 180:1665.
  13. Lu J, Gu J, Li K, et al. COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. *Emerg Infect Dis* 2020; 26:1628.
  14. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerg Infect Dis* 2020; 26:1583.
  15. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020; 323:1843.
  16. Li D, Jin M, Bao P, et al. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Netw Open* 2020; 3:e208292.
  17. Cevik M, Marcus JL, Buckee C, et al. SARS-CoV-2 transmission dynamics should inform policy. *Clin Infect Dis* 2020.
  18. Kakimoto K, Kamiya H, Yamagishi T, et al. Initial investigation of transmission of COVID-19 among crew members during quarantine of a cruise ship—Yokohama, Japan, February 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:312- 313.
  19. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514–523.
  20. Mosites E, Parker EM, Clarke KEN, et al. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U.S. Cities, March 27-April 15, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:521.
  21. Saloner B, Parish K, Ward JA, et al. COVID-19 Cases and Deaths in Federal and State Prisons. *JAMA* 2020; 324:602.
  22. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 Clusters on a University Campus - North Carolina, August 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:1416.
  23. Tenforde MW, Fisher KA, Patel MM. Identifying COVID-19 Risk Through Observational Studies to Inform Control Measures. *JAMA* 2021; 325:1464.
  24. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:411.
  25. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med* 2020; 17:e1003346.
  26. Otter JA, Donskey C, Yezli S, et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect* 2016; 92:235.
  27. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect* 2020; 104:246.
  28. Munnink BBO, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on mink

- farms between humans and mink and back to humans. *Science* 2020.
29. Newman A, Smith D, Ghai RR, et al. First Reported Cases of SARS-CoV-2 Infection in Companion Animals - New York, March-April 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(23): 710-3.
  30. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *The New England Journal of Medicine* 2020; 382 (13): 1199-1207. doi:10.1056/NEJMoa2001316
  31. Khalili M, Karamouzian M, Nasiri N, et al. Epidemiological Characteristics of COVID-19: A Systemic Review and Meta-Analysis. *medRxiv* 2020 doi:10.1101/2020.04.01.20050138
  32. Fontana LM, Villamagna AH, Sikka MK, et al. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. *Infect Control Hosp Epidemiol* 2021; 42:659.
  33. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell* 2020; 183:1901.
  34. Yuan J, Li M, Lv G, et al. Monitoring Transmissibility and Mortality of COVID-19 in Europe. *International Journal of Infectious Diseases* 2020; Mar 28, [Epub ahead of print]. doi:10.1016/j.ijid.2020.03.050
  35. Zhao S, Musa SS, Lin Q, et al. Estimating the unreported number of novel coronavirus (2019-nCoV) cases in China in the first half of January 2020: a datadriven modelling analysis of the early outbreak. *J Clin Med* 2020;9:388.
  36. Ji Y, Ma Z, Peppelenbosch MP, et al. Potential association between COVID-19 mortality and health-care resource availability. *The Lancet Global Health* 2020; 8 (4): e480. doi: 10.1016/S2214-109X(20)30068-1
  37. Istituto Superiore di Sanità (2020). Integrated surveillance of COVID-19 in Italy [online]. Website [https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica\\_6aprile%20ENG.pdf](https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica_6aprile%20ENG.pdf) [accessed 07 April 2020].
  38. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62.
  39. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious Diseases.* 2020; March 12, [Epub ahead of print]. doi: 10.1016/j.ijid.2020.03.017
  40. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021; 371.
  41. Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell* 2021; 184:169.
  42. Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. *Clin Infect Dis* 2020.
  43. Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature* 2021; 595:421.
  44. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* 2021; 384:533.
  45. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Intern Med* 2021; 181:672.
  46. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 2021; 397:1459.
  47. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* 2021; 397:1204.
  48. Mulder M, van der Vegt DSJM, Oude Munnink BB, et al. Reinfection of SARS-CoV-2 in an

- immunocompromised patient: a case report. *Clin Infect Dis* 2020.
49. Reported Cases and Deaths by Country. 18 Ağustos 2021. <https://www.worldometers.info/coronavirus/#countries>
  50. T.C. Sağlık Bakanlığı- COVID-19 Bilgilendirme Platformu. 18 Ağustos 2021. <https://COVID-19.saglik.gov.tr/>